stockportfolio.pro
ALNY vs CNC: Which Stock Is the Better Buy?
Alnylam Pharmaceuticals, Inc. and Centene Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ALNY vs CNC, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Alnylam Pharmaceuticals, Inc. (ALNY) | Centene Corporation (CNC) | |
|---|---|---|
| Market cap | $38.9B | $33.5B |
| Revenue (latest FY) | $3.71B | $194.78B |
| Net income (latest FY) | $313.75M | $-6.67B |
| Revenue growth (5y CAGR) | 49.8% | 11.9% |
| Net margin | 8.4% | -3.4% |
| Return on equity | 39.8% | -33.4% |
| P/E ratio | 73.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 9 |
| Positive free cash flow | Yes | Yes |
See the full ALNY vs CNC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ALNY's full financials → Open CNC's full financials →More comparisons
Frequently asked questions
Which is bigger, ALNY or CNC?
Alnylam Pharmaceuticals, Inc. is larger by market capitalization — $38.9B versus $33.5B.
Which grows faster, ALNY or CNC?
Over the last five fiscal years, Alnylam Pharmaceuticals, Inc. grew revenue faster — 49.8%/yr versus 11.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.